Constantin Schneider

Constantin Schneider

Auto-generated profile, based on publicly available information

Constantin Schneider

Department of Statistics, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
CSConstantin Schneider
Constantin Schneider
MRMatthew I J Raybould
Matthew I J Raybould
CDCharlotte M Deane
Charlotte M Deane
In 2013, we released the Structural Antibody Database (SAbDab), a publicly available repository of experimentally determined antibody structures. In the interim, the rapid increase in the number of antibody structure depositions to the Protein Data Bank, driven primarily by increased interest in antibodies as biotherapeutics, has led us to implement several improvements to the original database infrastructure. These include the development of SAbDab-nano, a sub-database that tracks nanobodies (heavy chain-only antibodies) which have seen a particular growth in attention from both the academic and pharmaceutical research communities over the past few years. Both SAbDab and SAbDab-nano are updated weekly, comprehensively annotated with the latest features described here, and are freely accessible at opig.stats.ox.ac.uk/webapps/newsabdab/.

21 September 2021 in Bioinformatics
Verified
Journal Article
Open access
PDF file
CSConstantin Schneider
Constantin Schneider
ABAndrew Buchanan
Andrew Buchanan
BTBruck Taddese
Bruck Taddese
CDCharlotte M Deane
Charlotte M Deane
Antibodies are one of the most important classes of pharmaceuticals, with over 80 approved molecules currently in use against a wide variety of diseases. The drug discovery process for antibody therapeutic candidates however is time- and cost-intensive and heavily reliant on in vivo and in vitro high throughput screens. Here, we introduce a framework for structure-based deep learning for antibodies (DLAB) which can virtually screen putative binding antibodies against antigen targets of interest. DLAB is built to be able to predict antibody–antigen binding for antigens with no known antibody binders. We demonstrate that DLAB can be used both to improve antibody–antigen docking and structure-based virtual screening of antibody drug candidates. DLAB enables improved pose ranking for antibody docking experiments as well as selection of antibody–antigen pairings for which accurate poses are generated and correctly ranked. We also show that DLAB can identify binding antibodies against specific antigens in a case study. Our results demonstrate the promise of deep learning methods for structure-based virtual screening of antibodies. The DLAB source code and pre-trained models are available at https://github.com/oxpig/dlab-public. Supplementary data are available at Bioinformatics online.

13 December 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
SRSarah A. Robinson
Sarah A. Robinson
MRMatthew I. J. Raybould
Matthew I. J. Raybould
CSConstantin Schneider
Constantin Schneider
WWWing Ki Wong
Wing Ki Wong
CMClaire Marks
Claire Marks
CDCharlotte M. Deane
Charlotte M. Deane
Identifying the epitope of an antibody is a key step in understanding its function and its potential as a therapeutic. Sequence-based clonal clustering can identify antibodies with similar epitope complementarity, however, antibodies from markedly different lineages but with similar structures can engage the same epitope. We describe a novel computational method for epitope profiling based on structural modelling and clustering. Using the method, we demonstrate that sequence dissimilar but functionally similar antibodies can be found across the Coronavirus Antibody Database, with high accuracy (92% of antibodies in multiple-occupancy structural clusters bind to consistent domains). Our approach functionally links antibodies with distinct genetic lineages, species origins, and coronavirus specificities. This indicates greater convergence exists in the immune responses to coronaviruses than is suggested by sequence-based approaches. Our results show that applying structural analytics to large class-specific antibody databases will enable high confidence structure-function relationships to be drawn, yielding new opportunities to identify functional convergence hitherto missed by sequence-only analysis.

19 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AHAlissa M. Hummer
Alissa M. Hummer
CSConstantin Schneider
Constantin Schneider
LCLewis Chinery
Lewis Chinery
CDCharlotte M. Deane
Charlotte M. Deane
Antibody-antigen binding affinity lies at the heart of therapeutic antibody development: efficacy is guided by specific binding and control of affinity. Here we present Graphinity, an equivariant graph neural network architecture built directly from antibody-antigen structures that achieves state-of-the-art performance on experimental ∆∆G prediction. However, our model, like previous methods, appears to be overtraining on the few hundred experimental data points available. To test if we could overcome this problem, we built a synthetic dataset of nearly 1 million FoldX-generated ∆∆G values. Graphinity achieved Pearson’s correlations nearing 0.9 and was robust to train-test cutoffs and noise on this dataset. The synthetic dataset also allowed us to investigate the role of dataset size and diversity in model performance. Our results indicate there is currently insufficient experimental data to accurately and robustly predict ∆∆G, with orders of magnitude more likely needed. Dataset size is not the only consideration – our tests demonstrate the importance of diversity. We also confirm that Graphinity can be used for experimental binding prediction by applying it to a dataset of > 36,000 Trastuzumab variants.

17 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MGMarco Giulini
Marco Giulini
CSConstantin Schneider
Constantin Schneider
DCDaniel Cutting
Daniel Cutting
NDNikita Desai
Nikita Desai
CDCharlotte M. Deane
Charlotte M. Deane
ABAlexandre M.J.J. Bonvin
Alexandre M.J.J. Bonvin
Antibody-antigen complex modelling is an important step in computational workflows for therapeutic antibody design. While experimentally determined structures of both antibody and the cognate antigen are often not available, recent advances in machine learning-driven protein modelling have enabled accurate prediction of both antibody and antigen structures. Here, we analyse the ability of protein-protein docking tools to use machine learning generated input structures for information-driven docking. We find that HADDOCK can generate accurate models of antibodyantigen complexes using an ensemble of antibody structures generated by machine learning tools and AlphaFold2 predicted antigen structures. Targeted docking using knowledge of the complementary determining regions on the antibody and some information about the targeted epitope allows the generation of high quality models of the complex with reduced sampling, resulting in a computationally cheap protocol that outperforms the ZDOCK baseline. The data set used to benchmark the docking protocols in this study is available at github.com/haddocking/ai-antibodies. The docking models will be deposited at data.sbgrid.org/labs/32/ upon acceptance.

14 February 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
CSConstantin Schneider
Constantin Schneider
ABAndrew Buchanan
Andrew Buchanan
BTBruck Taddese
Bruck Taddese
CDCharlotte M. Deane
Charlotte M. Deane
Antibodies are one of the most important classes of pharmaceuticals, with over 80 approved molecules currently in use against a wide variety of diseases. The drug discovery process for antibody therapeutic candidates however is time-and cost-intensive and heavily reliant on in-vivo and in-vitro high throughput screens. Here, we introduce a framework for structure-based deep learning for antibodies (DLAB) which can virtually screen putative binding antibodies against antigen targets of interest. DLAB is built to be able to predict antibody-antigen binding for antigens with no known antibody binders. We demonstrate that DLAB can be used both to improve antibody-antigen docking and structure-based virtual screening of antibody drug candidates. DLAB enables improved pose ranking for antibody docking experiments as well as selection of antibody-antigen pairings for which accurate poses are generated and correctly ranked. We also show that DLAB can identify binding antibodies against specific antigens in a case study. Our results demonstrate the promise of deep learning methods for structure-based virtual screening of antibodies.